Home > Research > Publications & Outputs > Pyridoxine in atopic dermatitis.
View graph of relations

Pyridoxine in atopic dermatitis.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Pyridoxine in atopic dermatitis. / Mabin, D. C.; Hollis, S.; Lockwood, J. et al.
In: British Journal of Dermatology, Vol. 133, No. 5, 1995, p. 764-767.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Mabin, DC, Hollis, S, Lockwood, J & David, TJ 1995, 'Pyridoxine in atopic dermatitis.', British Journal of Dermatology, vol. 133, no. 5, pp. 764-767. https://doi.org/10.1111/j.1365-2133.1995.tb02752.x

APA

Mabin, D. C., Hollis, S., Lockwood, J., & David, T. J. (1995). Pyridoxine in atopic dermatitis. British Journal of Dermatology, 133(5), 764-767. https://doi.org/10.1111/j.1365-2133.1995.tb02752.x

Vancouver

Mabin DC, Hollis S, Lockwood J, David TJ. Pyridoxine in atopic dermatitis. British Journal of Dermatology. 1995;133(5):764-767. doi: 10.1111/j.1365-2133.1995.tb02752.x

Author

Mabin, D. C. ; Hollis, S. ; Lockwood, J. et al. / Pyridoxine in atopic dermatitis. In: British Journal of Dermatology. 1995 ; Vol. 133, No. 5. pp. 764-767.

Bibtex

@article{422ef55a299f484382fb00db49daa480,
title = "Pyridoxine in atopic dermatitis.",
abstract = "Summary A previous study has reported benefit when pyridoxine hydrochloride was given to patients with atopic dermatitis. To investigate this in children, we performed a randomized, double-blind, parallel-group, placebo-controlled trial. Forty-eight children with moderate or severe atopic dermatitis were recruited and, of those who completed the study, 19 received pyridoxine hydrochloride 50 mg once daily for 4 weeks and 22 received placebo. Disease activity was monitored by clinical severity scores measuring the extent and degrees of erythema recorded by the investigator and symptom scores (daytime itch and nocturnal sleep disturbance) recorded by parents. There was no statistically significant difference between the two groups at the end of treatment. We have been unable to demonstrate clinical benefit from pyridoxine supplementation in children with atopic dermatitis.",
author = "Mabin, {D. C.} and S. Hollis and J. Lockwood and David, {T. J.}",
year = "1995",
doi = "10.1111/j.1365-2133.1995.tb02752.x",
language = "English",
volume = "133",
pages = "764--767",
journal = "British Journal of Dermatology",
issn = "1365-2133",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Pyridoxine in atopic dermatitis.

AU - Mabin, D. C.

AU - Hollis, S.

AU - Lockwood, J.

AU - David, T. J.

PY - 1995

Y1 - 1995

N2 - Summary A previous study has reported benefit when pyridoxine hydrochloride was given to patients with atopic dermatitis. To investigate this in children, we performed a randomized, double-blind, parallel-group, placebo-controlled trial. Forty-eight children with moderate or severe atopic dermatitis were recruited and, of those who completed the study, 19 received pyridoxine hydrochloride 50 mg once daily for 4 weeks and 22 received placebo. Disease activity was monitored by clinical severity scores measuring the extent and degrees of erythema recorded by the investigator and symptom scores (daytime itch and nocturnal sleep disturbance) recorded by parents. There was no statistically significant difference between the two groups at the end of treatment. We have been unable to demonstrate clinical benefit from pyridoxine supplementation in children with atopic dermatitis.

AB - Summary A previous study has reported benefit when pyridoxine hydrochloride was given to patients with atopic dermatitis. To investigate this in children, we performed a randomized, double-blind, parallel-group, placebo-controlled trial. Forty-eight children with moderate or severe atopic dermatitis were recruited and, of those who completed the study, 19 received pyridoxine hydrochloride 50 mg once daily for 4 weeks and 22 received placebo. Disease activity was monitored by clinical severity scores measuring the extent and degrees of erythema recorded by the investigator and symptom scores (daytime itch and nocturnal sleep disturbance) recorded by parents. There was no statistically significant difference between the two groups at the end of treatment. We have been unable to demonstrate clinical benefit from pyridoxine supplementation in children with atopic dermatitis.

U2 - 10.1111/j.1365-2133.1995.tb02752.x

DO - 10.1111/j.1365-2133.1995.tb02752.x

M3 - Journal article

VL - 133

SP - 764

EP - 767

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 1365-2133

IS - 5

ER -